BioCatalystWatch
ESPRWorkspace / ESPR / OverviewCompany library
Esperion Therapeutics, Inc. logo

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. (ESPR)

Website

Price
Market cap
Next catalystExpected 2026next-generation ACLY inhibitor (ESP-2001) · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

next-generation ACLY inhibitor (ESP-2001)

ACLY

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

next-generation ACLY inhibitor (ESP-2001)

ACLY

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

Approved / commercial

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ESPR PR & News

PR & News

ESPR SEC archive